Eiger Biopharmaceuticals (EIGR) has released an update to notify the public and investors about its officers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eldon Mayer III has resigned as the Chief Commercial Officer of Eiger BioPharmaceuticals, Inc., with his resignation set to take effect on February 2, 2024. He notified the company of his decision on January 18, 2024.
For further insights into EIGR corporate activity, check out TipRanks’ Insiders Trading Activity page.